VIDEO: Switching to latanoprostene bunod beneficial for lowering IOP

CHICAGO — In this Healio Video Perspective from the AAO meeting, Constance O. Okeke, MD, MSCE, discusses a study that investigated the impact of latanoprostene bunod on IOP in patients with open-angle glaucoma and ocular hypertension.

“We’re really excited about this data because what it could mean is further support that switching from a [prostaglandin analog] or a non-combination PGA medication to latanoprostene bunod, or Vyzulta [Bausch + Lomb], can be very beneficial for helping to lower the eye pressure,” she said. “Notably, with patients who have a non-combination treatment or if they are using it two to three times a day, being able to switch to a once-a-day medication can help with compliance and quality of life.”

Okeke also discusses the benefits of direct selective laser trabeculoplasty.

Published by:

Sources/Disclosures

Collapse

Source:

Okeke CO, et al. Reduction in IOP after switching to latanoprostene bunod in glaucoma patients in real-world clinical practice. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Disclosures:
Okeke reports being a consultant and speaker for Bausch + Lomb.

Read more about

This post was originally published on this site